Education
About Us
Working with TipRanks
Follow Us
Newamsterdam Pharma Company N.V. (NAMS)
:NAMS
Obicetrapib 10 Mg + Ezetimibe 10 Mg Fdc Daily, Obicetrapib 10 Mg
Lipidemia, Type 2 Diabetes (T2dm), Metabolic Syndrome (Mets)
Phase III
Not Yet Recruiting
A Study to Evaluate the Effect of Obicetrapib/Ezetimibe 10 mg Fixed-Dose Combination or Obicetrapib 10 mg Daily on Top of Guideline-Recommended Lipid-Lowering Therapy in Participants With Type 2 Diabetes and/or Metabolic Syndrome
Oct 20, 2025
―
Obicetrapib 10Mg
Antioxidant Absorption
Phase II
Recruiting
Evaluation of Obicetrapib on Antioxidant Levels in Plasma and HDL Particles of Healthy Volunteers
May 13, 2025
―
Obicetrapib 10Mg, Ezetimibe 10Mg
Healthy Volunteers
Phase I
Completed
A Study to Evaluate Drug-Drug Interactions of Obicetrapib Tablets and Ezetimibe Tablets in Healthy Adult Subjects
Aug 01, 2024
―
Obicetrapib 10 Mg + Obicetrapib/Evolocumab 140 Mg Q 2 Weeks
Dyslipidemias
Phase II
Recruiting
Impact of Obicetrapib and Obicetrapib Plus Repatha on Lp(a) Levels
Jul 03, 2024
―
Obicetrapib 10 Mg + Ezetimibe 10 Mg Fdc Daily
Coronary Artery Disease, Lipidemia, Plaque, Atherosclerotic
Phase III
Recruiting
A CCTA Imaging Trial to Evaluate the Effect of Obicetrapib/Ezetimibe on Coronary Plaque
Feb 28, 2024
―
Obicetrapib, Atorvastatin Calcium, Rosuvastatin Calcium
Healthy Volunteers
Phase I
Completed
A Drug-drug Interaction Study Evaluating the PK Effects of Obicetrapib on Atorvastatin and Rosuvastatin
Oct 03, 2023
―
Combination Therapy, Monotherapy Obicetrapib, Monotherapy Ezetimibe
Hypercholesterolemia, Familial Hypercholesterolemia, Dyslipidemias, High Cholesterol, Ascvd
Phase III
Completed
Study of Obicetrapib & Ezetimibe Fixed Dose Combination on Top of Maximum Tolerated Lipid-Modifying Therapies
Aug 15, 2023
―
Obicetrapib
Metabolic Disease, Hypercholesterolemia, Familial Hypercholesterolemia, Dyslipidemias, High Cholesterol, Genetic Disease, Inborn, Lipid Metabolism Disorder, Lipid Metabolism, Inborn Errors, Hyperlipoproteinemias
Phase III
Completed
Evaluate the Effect of Obicetrapib in Patients With HeFH on Top of Maximum Tolerated Lipid-Modifying Therapies.
Jun 15, 2022
―
Obicetrapib
Early Alzheimer's Disease
Phase II
Completed
Proof-of-concept, Open-label Study in Patients With Early Alzheimer's Disease
Nov 23, 2021
―
Obicetrapib
Atherosclerotic Cardiovascular Disease, Hypercholesterolemia, Familial Hypercholesterolemia, Dyslipidemias, High Cholesterol
Phase III
Completed
Randomized Study to Evaluate the Effect of Obicetrapib on Top of Maximum Tolerated Lipid-Modifying Therapies
Nov 18, 2021
―
FAQ
What are the FDA phases for drug approval?
The FDA approval process for new drugs is divided into several phases:
a. Preclinical testing
b. Phase 1 – Safety and dosage
c. Phase 2 – Effectiveness and side effects
d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments
e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
a. Preclinical testing
b. Phase 1 – Safety and dosage
c. Phase 2 – Effectiveness and side effects
d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments
e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
What is a clinical trial?
A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.
What drugs does Newamsterdam Pharma Company N.V. (NAMS) have in its pipeline
NAMS is currently developing the following drugs: Obicetrapib 10 Mg + Ezetimibe 10 Mg Fdc Daily, Obicetrapib 10 Mg, Obicetrapib 10Mg, Obicetrapib 10Mg, Ezetimibe 10Mg. These drug candidates are in various stages of clinical development as the company works toward FDA approval.